CRISPR forum early-bird rates closing soon

Discovered in 2012, CRISPR has been described as one of the biggest biotechnology discoveries of the century, offering possibilities that excite scientists involved in the field of medical research. Opening up new doors to combat cancer, HIV and many other diseases, CRISPR is expected to signal a significant change in the pharmaceutical and biotechnology industries and, perhaps, the future of human evolution.

To help scientists stay ahead of competition on the disruptive technologies that can transform R&D processes and open up new business directions, Clariden Global has announced its inaugural CRISPR Precise Genome Editing and Gene Modulation Forum, to be held from 5–7 December at InterContinental Melbourne the Rialto.

The forum will shed light on the latest CRISPR innovations and bring forward the best practices from the industry leaders. Attendees can expect to discover the current challenges, explore possible solutions and unfold the strategic considerations they should take before adopting this new genome editing tool.

Participants in the forum will hear from the industry experts and first movers in the region to discover new opportunities to bring CRISPR to the laboratory. They will also have the opportunity to reach out to the relevant regulatory bodies to explore the potential of the technology and push innovation for the region.

Early-bird rates are open until 8 November, enabling attendees to save up to $100. For more information and to register, visit http://claridenglobal.com/conference/crispr-au2016/.